IDYA
IDEAYA Biosciences, Inc.
There isn't enough reported data to score IDYA yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
IDYA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
IDYA's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
IDYA PE Valuation
IDYA has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
IDYA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IDYA's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
IDYA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.46 | -$2.54 |
| Q2 2026 | -$1.91 | +$1.94 |
| Q1 2026 | -$1.57 | +$2.08 |
| Q4 2025 | -$1.28 | +$2.08 |
| Q3 2025 | -$1.92 | +$0.40 |
| Q2 2025 | -$3.85 | -$1.67 |
| Q1 2025 | -$3.65 | -$1.65 |
| Q4 2024 | -$3.36 | -$1.40 |
IDYA lost $4.46 per share over the past year, and its loss has widened in each of the last three quarters.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over IDYA on earnings quality, reporting a profit while its opponent remains loss making.
IDYA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.2M | -95% |
| Q4 2025 | $10.9M | +55% |
| Q4 2024 | $7M | +78% |
| Q4 2023 | $3.9M | -2.5% |
| Q3 2023 | $8M | -73% |
| Q2 2023 | $3.5M | -39% |
| Q1 2023 | $7.9M | -31% |
| Q4 2022 | $4M | +36% |
IDYA's revenue has slid since its 2025 peak: $10M last quarter, down 95% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1344% | -1396 points |
| Q2 2026 | -1381% | N/A |
| Q1 2026 | -1655% | N/A |
| Q4 2025 | -870% | +1190 points |
| Q3 2025 | 52% | N/A |
| Q4 2024 | -2059% | -990 points |
| Q4 2023 | -1069% | -411 points |
| Q3 2023 | -417% | -419 points |
IDYA's operating margin was −1344% last quarter, down 1396 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over IDYA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over IDYA on profitability, with a higher operating margin.
IDYA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$93.8M | -166% |
| Q2 2026 | -$89.1M | -$25.9M |
| Q1 2026 | -$76.1M | -$14.5M |
| Q4 2025 | -$90.8M | +$31.9M |
| Q3 2025 | $142.2M | +$191.9M |
| Q2 2025 | -$63.1M | -$29.3M |
| Q1 2025 | -$61.7M | -$16.5M |
| Q4 2024 | -$122.8M | -$98.2M |
IDYA has burned cash in almost every quarter: −$350M over the past year, against −$105M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over IDYA on cash generation, producing positive trailing cash flow while its opponent burns cash.
IDYA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +12% | +10.9M shares |
| 1 year | +15% | +13.3M shares |
| 3 years | +83% | +46.7M shares |
| 5 years | +213% | +70.1M shares |
| Available history | +408% | +82.7M shares |
IDYA has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IDYA Net Leverage
IDYA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
IDYA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 5.8 | Oversold |
IDYA's weekly RSI is 42 (neutral) and its Stochastic is 6 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
IDYA PE vs Healthcare Sector
IDYA has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
IDYA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.1 | 7.5% below |
| 20 week MA | $36.2 | 13% below |
| 50 week MA | $33.8 | 6.7% below |
| 100 week MA | $28.6 | 10% above |
| 200 week MA | $29.5 | 6.6% above |
IDYA has slipped below its 8-, 20- and 50-week averages, though it's still 6.6% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over IDYA on trend strength, trading above more of its moving averages.
IDYA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.50 | $12.9 | +52% |
| 2021 | $12.9 | $23.4 | +81% |
| 2022 | $23.4 | $17.0 | -27% |
| 2023 | $17.0 | $35.6 | +109% |
| 2024 | $35.6 | $25.2 | -29% |
| 2025 | $25.2 | $35.2 | +40% |
| 2026 YTD | $35.2 | $31.5 | -11% |
IDYA has finished higher in four of the last six years, three of them by more than 50%. It's down 11% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over IDYA on returns for 2026, with the stronger performance.